New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.
New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.
复制标题
DOI:
10.1161/circulationaha.113.007980
复制
发表时间:
2014-07-01
期刊:
影响因子:
37.8
通讯作者:
Redington AN
中科院分区:
文献类型:
--
作者:
Burns KM;Byrne BJ;Gelb BD;Kühn B;Leinwand LA;Mital S;Pearson GD;Rodefeld M;Rossano JW;Stauffer BL;Taylor MD;Towbin JA;Redington AN
Pediatric heart failure (HF) is the inability of the heart of an infant, child, or adolescent to meet the body’s metabolic demands. It involves circulatory, neurohumoral, and molecular abnormalities that manifest as edema, respiratory distress, growth failure, and exercise intolerance. The myriad causes include inherited and acquired myocardial anomalies (cardiomyopathy [CM]), volume overload (intracardiac shunts, valvular regurgitation), and the unique hemodynamics predicated by a functional single ventricle (palliated complex congenital heart disease [CHD]).Although the societal and financial costs of adult HF are well known, the burden of pediatric HF is less familiar, but no less onerous. New-onset HF requiring hospital admission occurs in 0.87 per 100 000 children, 1 yet that does not include the growing population with CHD-related HF. In 2006, there were nearly 14 000 pediatric hospitalizations for HF from all causes in the United States. 2 The rate of HF-related admissions was nearly 18 per 100 000 children, 2 which is comparable to severe sepsis. 3